Dendritic cells in cancer immunology and immunotherapy

被引:1095
|
作者
Wculek, Stefanie K. [1 ]
Cueto, Francisco J. [1 ]
Mujal, Adriana M. [2 ,7 ]
Melero, Ignacio [3 ,4 ,5 ,6 ]
Krummel, Matthew F. [2 ]
Sancho, David [1 ]
机构
[1] CNIC, Immunobiol Lab, Madrid, Spain
[2] Univ Calif San Francisco, Dept Pathol, San Francisco, CA 94140 USA
[3] Univ Navarra, Ctr Appl Med Res, Div Immunol & Immunotherapy, Pamplona, Spain
[4] Inst Invest Sanitaria Navarra, Pamplona, Spain
[5] Univ Navarra, Univ Clin, Pamplona, Spain
[6] Ctr Invest Biomed Red Canc, Madrid, Spain
[7] Mem Sloan Kettering Canc Ctr, Immunol Program, 1275 York Ave, New York, NY 10021 USA
基金
欧洲研究理事会; 欧盟地平线“2020”;
关键词
ANTIGEN CROSS-PRESENTATION; CD8(+) T-CELLS; IMMUNE-RESPONSES; ANTITUMOR IMMUNITY; BETA-CATENIN; FLT3; LIGAND; ANTICANCER CHEMOTHERAPY; COINHIBITORY RECEPTOR; I INTERFERON; VACCINES;
D O I
10.1038/s41577-019-0210-z
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
Dendritic cells (DCs) are a diverse group of specialized antigen-presenting cells with key roles in the initiation and regulation of innate and adaptive immune responses. As such, there is currently much interest in modulating DC function to improve cancer immunotherapy. Many strategies have been developed to target DCs in cancer, such as the administration of antigens with immunomodulators that mobilize and activate endogenous DCs, as well as the generation of DC-based vaccines. A better understanding of the diversity and functions of DC subsets and of how these are shaped by the tumour microenvironment could lead to improved therapies for cancer. Here we will outline how different DC subsets influence immunity and tolerance in cancer settings and discuss the implications for both established cancer treatments and novel immunotherapy strategies.
引用
收藏
页码:7 / 24
页数:18
相关论文
共 50 条
  • [1] Dendritic cells in cancer immunology and immunotherapy
    Stefanie K. Wculek
    Francisco J. Cueto
    Adriana M. Mujal
    Ignacio Melero
    Matthew F. Krummel
    David Sancho
    [J]. Nature Reviews Immunology, 2020, 20 : 7 - 24
  • [2] Dendritic Cells in Cancer Immunology and Immunotherapy
    Hato, Laura
    Vizcay, Angel
    Eguren, Inaki
    Perez-Gracia, Jose L.
    Rodriguez, Javier
    Perez-Larraya, Jaime Gallego
    Sarobe, Pablo
    Inoges, Susana
    de Cerio, Ascension Lopez Diaz
    Santisteban, Marta
    [J]. CANCERS, 2024, 16 (05)
  • [3] Dendritic cells in tumor immunology and immunotherapy
    Turtle, CJ
    Hart, DNJ
    [J]. CURRENT DRUG TARGETS, 2004, 5 (01) : 17 - 39
  • [4] Dendritic cells in cancer immunology
    Kreutz, M.
    Gottfried, E.
    Kunz-Schughart, L. A.
    Hoves, S.
    Andreesen, R.
    Mackensen, A.
    [J]. CYTOMETRY PART B-CLINICAL CYTOMETRY, 2008, 74B (01) : 58 - 58
  • [5] Dendritic cells in cancer immunology
    Murphy, Theresa L.
    Murphy, Kenneth M.
    [J]. CELLULAR & MOLECULAR IMMUNOLOGY, 2022, 19 (01) : 3 - 13
  • [6] Dendritic cells in cancer immunology
    Theresa L. Murphy
    Kenneth M. Murphy
    [J]. Cellular & Molecular Immunology, 2022, 19 : 3 - 13
  • [7] Dendritic cells in cancer immunotherapy
    Gunzer, M
    Grabbe, S
    [J]. CRITICAL REVIEWS IN IMMUNOLOGY, 2001, 21 (1-3) : 133 - 145
  • [8] Cancer immunotherapy by dendritic cells
    Melief, Cornelis J. M.
    [J]. IMMUNITY, 2008, 29 (03) : 372 - 383
  • [9] Dendritic Cells and Immunotherapy for Cancer
    David H. Chang
    Madhav V. Dhodapkar
    [J]. International Journal of Hematology, 2003, 77 : 439 - 443
  • [10] Dendritic cells and immunotherapy for cancer
    Chang, DH
    Dhodapkar, MV
    [J]. INTERNATIONAL JOURNAL OF HEMATOLOGY, 2003, 77 (05) : 439 - 443